Optimizing assessments of quality of life in contemporary prostate cancer clinical trials

Abstract

This editorial reviews the associations between quality of life (QOL) and prognosis in cancer clinical trials, and considers whether they may be different in the era of radioligand therapy. It also outlines novel approaches to QOL analysis that may enhance our ability to use patient‐reported outcomes in treatment decisions more effectively in the future.